Table of Contents Author Guidelines Submit a Manuscript
Analytical Cellular Pathology
Volume 2015 (2015), Article ID 150634, 8 pages
http://dx.doi.org/10.1155/2015/150634
Review Article

Chemoresistance, Cancer Stem Cells, and miRNA Influences: The Case for Neuroblastoma

1School of Clinical Sciences, Faculty of Medicine and Dentistry, University of Bristol, Bristol BS8 1TH, UK
2Centre for Molecular Medicine and Biobanking, University of Malta, Msida MSD 2080, Malta
3Faculty of Medical and Human Sciences, The University of Manchester, Manchester M1 7DN, UK

Received 29 April 2015; Revised 26 June 2015; Accepted 1 July 2015

Academic Editor: Nils Ole Schmidt

Copyright © 2015 Alfred Buhagiar and Duncan Ayers. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Gherardi, E. Valli, D. Erriquez, and G. Perini, “MYCN-mediated transcriptional repression in neuroblastoma: the other side of the coin,” Frontiers in Oncology, vol. 3, article 42, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. MD Anderson Cancer Center, Neuroblastoma Cancer Facts & Information, 2015, http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/neuroblastoma/index.html.
  3. Neuroblastoma in children, 2013, http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Childrenscancers/Typesofchildrenscancers/Neuroblastoma.aspx.
  4. J. Buechner and C. Einvik, “N-myc and noncoding RNAs in neuroblastoma,” Molecular Cancer Research, vol. 10, no. 10, pp. 1243–1253, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. R. P. Castleberry, “Neuroblastoma,” European Journal of Cancer, vol. 33, no. 9, pp. 1430–1438, 1990. View at Google Scholar
  6. L. Moreno, L. V. Marshall, and A. D. J. Pearson, “At the frontier of progress for paediatric oncology: the neuroblastoma paradigm,” British Medical Bulletin, vol. 108, no. 1, pp. 173–188, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Bourdeaut, D. Trochet, I. Janoueix-Lerosey et al., “Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma,” Cancer Letters, vol. 228, no. 1-2, pp. 51–58, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. J. M. Maris, “Recent advances in neuroblastoma,” The New England Journal of Medicine, vol. 362, no. 23, pp. 2202–2211, 2010. View at Google Scholar
  9. Y. P. Mossé, M. Laudenslager, L. Longo et al., “Identification of ALK as a major familial neuroblastoma predisposition gene,” Nature, vol. 455, no. 7215, pp. 930–935, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. T. R. Webb, J. Slavish, R. E. George et al., “Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy,” Expert Review of Anticancer Therapy, vol. 9, no. 3, pp. 331–356, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Chen, J. Takita, Y. L. Choi et al., “Oncogenic mutations of ALK kinase in neuroblastoma,” Nature, vol. 455, no. 7215, pp. 971–974, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. C. Bresler, D. A. Weiser, P. J. Huwe et al., “ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma,” Cancer Cell, vol. 26, no. 5, pp. 682–694, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. J. M. Maris and K. K. Matthay, “Molecular biology of neuroblastoma,” Journal of Clinical Oncology, vol. 17, no. 7, pp. 2264–2279, 1999. View at Google Scholar
  14. M. A. Hayat, Ed., Neuroblastoma, vol. 1 of Pediatric Cancer, Springer, Dordrecht, The Netherlands, 2012. View at Publisher · View at Google Scholar
  15. M. Yoshimoto, S. R. C. de Toledo, E. M. Monteiro Caran et al., “MYCN gene amplification,” The American Journal of Pathology, vol. 155, no. 5, pp. 1439–1443, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. K. De Preter, J. Vandesompele, P. Heimann et al., “Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes,” Genome Biology, vol. 7, no. 9, article R84, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. L. J. Valentijn, J. Koster, F. Haneveld et al., “Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 47, pp. 19190–19195, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. L. M. Hansford, W. D. Thomas, J. M. Keating et al., “Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 34, pp. 12664–12669, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. J. J. Molenaar, R. Domingo-Fernández, M. E. Ebus et al., “LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression,” Nature Genetics, vol. 44, no. 11, pp. 1199–1206, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Yu, M. A. Vodyanik, K. Smuga-Otto et al., “Induced pluripotent stem cell lines derived from human somatic cells,” Science, vol. 318, no. 5858, pp. 1917–1920, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. J. M. Shohet, “Redefining functional MYCN gene signatures in neuroblastoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 47, pp. 19041–19042, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Mestdagh, E. Fredlund, F. Pattyn et al., “MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors,” Oncogene, vol. 29, no. 9, pp. 1394–1404, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Zhi, R. Wang, Q. Wang et al., “MicroRNAs in neuroblastoma: small-sized players with a large impact,” Neurochemical Research, vol. 39, no. 4, pp. 613–623, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Bottino, A. Dondero, F. Bellora et al., “Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches,” Frontiers in Immunology, vol. 5, article 56, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. National Cancer Institute, Neuroblastoma Treatment, 2015, http://www.cancer.gov/cancertopics/pdq/treatment/neuroblastoma/HealthProfessional/page9.
  26. S. Mueller and K. K. Matthay, “Neuroblastoma: biology and staging,” Current Oncology Reports, vol. 11, no. 6, pp. 431–438, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. G. M. Brodeur, J. Pritchard, F. Berthold et al., “Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment,” Progress in Clinical and Biological Research, vol. 385, pp. 363–369, 1994. View at Google Scholar · View at Scopus
  28. T. Monclair, G. M. Brodeur, P. F. Ambros et al., “The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report,” Journal of Clinical Oncology, vol. 27, no. 2, pp. 298–303, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. R. C. Lee, R. L. Feinbaum, and V. Ambros, “The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14,” Cell, vol. 75, no. 5, pp. 843–854, 1993. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Di Leva, M. Garofalo, and C. M. Croce, “MicroRNAs in cancer,” Annual Review of Pathology, vol. 9, pp. 287–314, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. R. W. Carthew and E. J. Sontheimer, “Origins and mechanisms of miRNAs and siRNAs,” Cell, vol. 136, no. 4, pp. 642–655, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. F. L. Kisseljov, “MicroRNAs and cancer,” Molecular Biology, vol. 48, no. 2, pp. 197–206, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Volinia, G. A. Calin, C.-G. Liu et al., “A microRNA expression signature of human solid tumors defines cancer gene targets,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 7, pp. 2257–2261, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. X. Wang, L. Cao, Y. Wang, X. Wang, N. Liu, and Y. You, “Regulation of let-7 and its target oncogenes (review),” Oncology Letters, vol. 3, no. 5, pp. 955–960, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Mogilyansky and I. Rigoutsos, “The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease,” Cell Death and Differentiation, vol. 20, no. 12, pp. 1603–1614, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. X. Chen, B. Hao, G. Han et al., “miR-372 regulates glioma cell proliferation and invasion by directly targeting PHLPP2,” Journal of Cellular Biochemistry, vol. 116, no. 2, pp. 225–232, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. C. Chan, J. Banerjee, S. Y. Choi, and C. K. Sen, “miR-210: the master hypoxamir,” Microcirculation, vol. 19, no. 3, pp. 215–223, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Tsukerman, R. Yamin, E. Seidel et al., “MiR-520d-5p directly targets TWIST1 and downregulates the metastamiR miR-10b,” Oncotarget, vol. 5, no. 23, pp. 12141–12150, 2014. View at Google Scholar · View at Scopus
  39. L. Ma, J. Teruya-Feldstein, and R. A. Weinberg, “Tumour invasion and metastasis initiated by microRNA-10b in breast cancer,” Nature, vol. 449, no. 7163, pp. 682–688, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. D. B. Longley and P. G. Johnston, “Molecular mechanisms of drug resistance,” Journal of Pathology, vol. 205, no. 2, pp. 275–292, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Ayers and A. Nasti, “Utilisation of nanoparticle technology in cancer chemoresistance,” Journal of Drug Delivery, vol. 2012, Article ID 265691, 12 pages, 2012. View at Publisher · View at Google Scholar
  42. T. R. Wilson, D. B. Longley, and P. G. Johnston, “Chemoresistance in solid tumours,” Annals of Oncology, vol. 17, supplement 10, pp. x315–x324, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. J.-P. Gillet and M. M. Gottesman, “Mechanisms of multidrug resistance in cancer,” in Multi-Drug Resistance in Cancer, vol. 596 of Methods in Molecular Biology, pp. 47–76, Humana Press, Clifton, NJ, USA, 2010. View at Publisher · View at Google Scholar
  44. M. Rebucci and C. Michiels, “Molecular aspects of cancer cell resistance to chemotherapy,” Biochemical Pharmacology, vol. 85, no. 9, pp. 1219–1226, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. A. K. Nagaraja, C. J. Creighton, Z. Yu et al., “A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer,” Molecular Endocrinology, vol. 24, no. 2, pp. 447–463, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. M. R. Abedini, E. J. Muller, R. Bergeron, D. A. Gray, and B. K. Tsang, “Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein,” Oncogene, vol. 29, no. 1, pp. 11–25, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Wu, Y. Cao, D. Weng et al., “Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms,” Cancer Letters, vol. 271, no. 2, pp. 260–271, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Gadea, M. de Toledo, C. Anguille, and P. Roux, “Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices,” Journal of Cell Biology, vol. 178, no. 1, pp. 23–30, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Arsic, G. Gadea, E. Lagerqvist et al., “The p53 isoform Δ133p53β promotes cancer stem cell potential,” Stem Cell Reports, vol. 4, no. 4, pp. 531–540, 2015. View at Publisher · View at Google Scholar
  50. P. A. J. Muller, P. T. Caswell, B. Doyle et al., “Mutant p53 drives invasion by promoting integrin recycling,” Cell, vol. 139, no. 7, pp. 1327–1341, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Lai, S. Visser-Grieve, and X. Yang, “Tumour suppressor genes in chemotherapeutic drug response,” Bioscience Reports, vol. 32, no. 4, pp. 361–374, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. W. B. Nagengast, T. H. O. Munnink, E. C. F. Dijkers et al., “Multidrug resistance in oncology and beyond: from imaging of drug efflux pumps to cellular drug targets,” Methods in Molecular Biology, vol. 596, pp. 15–31, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Ghavami, M. Hashemi, S. R. Ande et al., “Apoptosis and cancer: mutations within caspase genes,” Journal of Medical Genetics, vol. 46, no. 8, pp. 497–510, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. F. H. Igney and P. H. Krammer, “Death and anti-death: tumour resistance to apoptosis,” Nature Reviews Cancer, vol. 2, no. 4, pp. 277–288, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. P. Vaupel and A. Mayer, “Hypoxia and anemia: effects on tumor biology and treatment resistance,” Transfusion Clinique et Biologique, vol. 12, no. 1, pp. 5–10, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. P. Vaupel and A. Mayer, “Hypoxia in cancer: significance and impact on clinical outcome,” Cancer and Metastasis Reviews, vol. 26, no. 2, pp. 225–239, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. J.-P. Cosse and C. Michiels, “Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression,” Anti-Cancer Agents in Medicinal Chemistry, vol. 8, no. 7, pp. 790–797, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. R. Straussman, T. Morikawa, K. Shee et al., “Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion,” Nature, vol. 487, no. 7408, pp. 500–504, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. Y. Mao, E. T. Keller, D. H. Garfield, K. Shen, and J. Wang, “Stromal cells in tumor microenvironment and breast cancer,” Cancer and Metastasis Reviews, vol. 32, no. 1-2, pp. 303–315, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. R. Lanza and A. Atala, Eds., Essentials of Stem Cell Biology, Academic Press, Amsterdam, The Netherlands, 3rd edition, 2013.
  62. K. Takahashi, K. Tanabe, M. Ohnuki et al., “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,” Cell, vol. 131, no. 5, pp. 861–872, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Bongso, Stem Cells: From Bench to Bedside, E. H. Lee, Ed., World Scientific Publishing, Hackensack, NJ, USA, 2nd edition, 2010.
  64. T. Lapidot, C. Sirard, J. Vormoor et al., “A cell initiating human acute myeloid leukaemia after transplantation into SCID mice,” Nature, vol. 367, no. 6464, pp. 645–648, 1994. View at Publisher · View at Google Scholar · View at Scopus
  65. P. Borst, “Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?” Open Biology, vol. 2, no. 5, Article ID 120066, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. S. J. Morrison and J. Kimble, “Asymmetric and symmetric stem-cell divisions in development and cancer,” Nature, vol. 441, no. 7097, pp. 1068–1074, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. L. Shahriyari and N. L. Komarova, “Symmetric vs. asymmetric stem cell divisions: an adaptation against cancer?” PLoS ONE, vol. 8, no. 10, Article ID e76195, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. Z. Yu, T. G. Pestell, M. P. Lisanti, and R. G. Pestell, “Cancer stem cells,” International Journal of Biochemistry and Cell Biology, vol. 44, no. 12, pp. 2144–2151, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. I. Ischenko, H. Seeliger, M. Schaffer, K.-W. Jauch, and C. J. Bruns, “Cancer stem cells: how can we target them?” Current Medicinal Chemistry, vol. 15, no. 30, pp. 3171–3184, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Chiba, “Notch signaling in stem cell systems,” Stem Cells, vol. 24, no. 11, pp. 2437–2447, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. H. J. Kraft, S. Mosselman, H. A. Smits et al., “Oct-4 regulates alternative platelet-derived growth factor α receptor gene promoter in human embryonal carcinoma cells,” Journal of Biological Chemistry, vol. 271, no. 22, pp. 12873–12878, 1996. View at Publisher · View at Google Scholar · View at Scopus
  72. L. Gao, Y. Yang, H. Xu et al., “MiR-335 functions as a tumor suppressor in pancreatic cancer by targeting OCT4,” Tumour Biology, vol. 35, no. 8, pp. 8309–8318, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. P. A. Beachy, S. S. Karhadkar, and D. M. Berman, “Tissue repair and stem cell renewal in carcinogenesis,” Nature, vol. 432, no. 7015, pp. 324–331, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. L. Li and W. B. Neaves, “Normal stem cells and cancer stem cells: the niche matters,” Cancer Research, vol. 66, no. 9, pp. 4553–4557, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. P. Neveu, M. J. Kye, S. Qi et al., “MicroRNA profiling reveals two distinct p53-related human pluripotent stem cell states,” Cell Stem Cell, vol. 7, no. 6, pp. 671–681, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. M. M. Sherry, A. Reeves, J. K. Wu, and B. H. Cochran, “STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells,” Stem Cells, vol. 27, no. 10, pp. 2383–2392, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. D. M. Hsu, S. Agarwal, A. Benham et al., “G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic,” Cancer Research, vol. 73, no. 13, pp. 4134–4146, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. M. M. Gottesman, T. Fojo, and S. E. Bates, “Multidrug resistance in cancer: role of ATP-dependent transporters,” Nature Reviews Cancer, vol. 2, no. 1, pp. 48–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  79. T. Zheng, J. Wang, X. Chen, and L. Liu, “Role of microRNA in anticancer drug resistance,” International Journal of Cancer, vol. 126, no. 1, pp. 2–10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. Y.-Z. Pan, M. E. Morris, and A.-M. Yu, “MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells,” Molecular Pharmacology, vol. 75, no. 6, pp. 1374–1379, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. H. Zhu, H. Wu, X. Liu et al., “Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells,” Biochemical Pharmacology, vol. 76, no. 5, pp. 582–588, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. O. Kovalchuk, J. Filkowski, J. Meservy et al., “Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin,” Molecular Cancer Therapeutics, vol. 7, no. 7, pp. 2152–2159, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. M. Dean, T. Fojo, and S. Bates, “Tumour stem cells and drug resistance,” Nature Reviews Cancer, vol. 5, no. 4, pp. 275–284, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Gisel, M. Valvano, I. G. El Idrissi et al., “MiRNAs for the detection of multidrug resistance: overview and perspectives,” Molecules, vol. 19, no. 5, pp. 5611–5623, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. Y. Shi, J. Wang, Z. Xin et al., “Transcription factors and microRNA-co-regulated genes in gastric cancer invasion in ex vivo,” PLoS ONE, vol. 10, no. 4, Article ID e0122882, 2015. View at Publisher · View at Google Scholar
  86. G. A. Calin, C. Sevignani, C. D. Dumitru et al., “Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 2999–3004, 2004. View at Publisher · View at Google Scholar · View at Scopus
  87. L. Fontana, M. E. Fiori, S. Albini et al., “Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM,” PLoS ONE, vol. 3, no. 5, Article ID e2236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. H. Mei, Z.-Y. Lin, and Q.-S. Tong, “The roles of microRNAs in neuroblastoma,” World Journal of Pediatrics, vol. 10, no. 1, pp. 10–16, 2014. View at Publisher · View at Google Scholar · View at Scopus
  89. J. Lovén, N. Zinin, T. Wahlström et al., “MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 4, pp. 1553–1558, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. R. L. Stallings, “MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics,” Current Pharmaceutical Design, vol. 15, no. 4, pp. 456–462, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. P. Mestdagh, A.-K. Boström, F. Impens et al., “The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma,” Molecular Cell, vol. 40, no. 5, pp. 762–773, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. Y. Chen, Y.-H. Tsai, Y. Fang, and S.-H. Tseng, “Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells,” Journal of Pediatric Surgery, vol. 47, no. 10, pp. 1797–1805, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Guidi, M. Muiños-Gimeno, B. Kagerbauer, E. Martí, X. Estivill, and Y. Espinosa-Parrilla, “Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SH-SY5Y neuroblastoma cells,” BMC Molecular Biology, vol. 11, article 95, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Swarbrick, S. L. Woods, A. Shaw et al., “MiR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma,” Nature Medicine, vol. 16, no. 10, pp. 1134–1140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. H. Qu, L. Zheng, J. Pu et al., “miRNA-558 promotes tumorigenesis and aggressiveness of neuroblastoma cells through activating the transcription of heparanase,” Human Molecular Genetics, vol. 24, no. 9, pp. 2539–2551, 2015. View at Publisher · View at Google Scholar
  96. L. Samaraweera, K. B. Grandinetti, R. Huang, B. A. Spengler, and R. A. Ross, “MicroRNAs define distinct human neuroblastoma cell phenotypes and regulate their differentiation and tumorigenicity,” BMC Cancer, vol. 14, article 309, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. A. M. Lozier, M. E. Rich, A. P. Grawe et al., “Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma,” Oncotarget, vol. 6, no. 1, pp. 196–206, 2015. View at Google Scholar · View at Scopus
  98. H. Zhang, M. Qi, S. Li et al., “MicroRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells,” Molecular Cancer Therapeutics, vol. 11, no. 7, pp. 1454–1466, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. W. C. S. Cho, “OncomiRs: the discovery and progress of microRNAs in cancers,” Molecular Cancer, vol. 6, article 60, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Bottoni, D. Piccin, F. Tagliati, A. Luchin, M. C. Zatelli, and E. C. D. Uberti, “miR-15a and miR-16-1 down-regulation in pituitary adenomas,” Journal of Cellular Physiology, vol. 204, no. 1, pp. 280–285, 2005. View at Publisher · View at Google Scholar · View at Scopus
  101. S. Moncini, A. Salvi, P. Zuccotti et al., “The role of miR-103 and miR-107 in regulation of CDK5R1 expression and in cellular migration,” PLoS ONE, vol. 6, no. 5, Article ID e20038, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. P. Zuccotti, C. Colombrita, S. Moncini et al., “HnRNPA2/B1 and nELAV proteins bind to a specific U-rich element in CDK5R1 3′-UTR and oppositely regulate its expression,” Biochimica et Biophysica Acta—Gene Regulatory Mechanisms, vol. 1839, no. 6, pp. 506–516, 2014. View at Publisher · View at Google Scholar · View at Scopus
  103. L.-C. Cheng, E. Pastrana, M. Tavazoie, and F. Doetsch, “MiR-124 regulates adult neurogenesis in the subventricular zone stem cell niche,” Nature Neuroscience, vol. 12, no. 4, pp. 399–408, 2009. View at Publisher · View at Google Scholar · View at Scopus
  104. X. Cao, S. L. Pfaff, and F. H. Gage, “A functional study of miR-124 in the developing neural tube,” Genes & Development, vol. 21, no. 5, pp. 531–536, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. I. Y. Cheung, T. A. Farazi, I. Ostrovnaya et al., “Deep MicroRNA sequencing reveals downregulation of miR-29a in neuroblastoma central nervous system metastasis,” Genes Chromosomes and Cancer, vol. 53, no. 10, pp. 803–814, 2014. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Das, N. Foley, K. Bryan et al., “MicroRNA mediates DNA de-methylation events triggered by retinoic acid during neuroblastoma cell differentiation,” Cancer Research, vol. 70, no. 20, pp. 7874–7881, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. P. Laneve, L. Di Marcotullio, U. Gioia et al., “The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 19, pp. 7957–7962, 2007. View at Publisher · View at Google Scholar · View at Scopus
  108. J. Ryan, A. Tivnan, J. Fay et al., “MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome,” British Journal of Cancer, vol. 107, no. 6, pp. 967–976, 2012. View at Publisher · View at Google Scholar · View at Scopus
  109. J. Qiao, S. Lee, P. Paul et al., “MiR-335 and miR-363 regulation of neuroblastoma tumorigenesis and metastasis,” Surgery, vol. 154, no. 2, pp. 226–233, 2013. View at Publisher · View at Google Scholar · View at Scopus
  110. P. E. Blower, J.-H. Chung, J. S. Verducci et al., “MicroRNAs modulate the chemosensitivity of tumor cells,” Molecular Cancer Therapeutics, vol. 7, no. 1, pp. 1–9, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. J. Wang, J. Chen, P. Chang et al., “MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease,” Cancer Prevention Research, vol. 2, no. 9, pp. 807–813, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. F. H. Sarkar, Ed., MicroRNA Targeted Cancer Therapy, Springer, New York, NY, USA, 2014.